Abstract
Stereotactic Body Radiation Therapy (SBRT) has quickly been adopted as the standard of care for inoperable early-stage NSCLC, with consistently reported local control rates > 90%, improving upon historical means. However, data directly comparing the outcomes of SBRT with those of conventionally fractionated radiotherapy (CONV) is lacking. A randomized trial addressing this question is ongoing in Australia. Here we report our institutional experience in treating early-stage NSCLC with CONV and SBRT.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call